GEORGETTES LMR PMHNP
CERTIFICATION EXAM MASTERY
VAULT DETAILED CORRECT
ANSWERS WITH RATIONALES
AND CORRECT VERIFIED
ANSWERS FOR A GRADE A+
PERFORMANCE
1. A 42-year-old corporate executive presents with a 7-month
history of progressive cognitive deterioration, distinct
memory gaps, and involuntary, sudden jerking
movements of his upper extremities. The Psychiatric-
Mental Health Nurse Practitioner (PMHNP) orders an
electroencephalogram (EEG), which demonstrates a
classic diagnostic profile of periodic, sharp wave
complexes occurring at 1-second intervals. Given this
clinical presentation and neurophysiological profile, what
is the most likely diagnosis?
A. Early-onset Alzheimer's type dementia with pseudo-
bulbar symptoms.
B. Creutzfeldt-Jakob disease, characterized by rapid prion-
mediated neurodegeneration.
C. Wernicke-Korsakoff syndrome secondary to chronic
thiamine malabsorption.
D. Pick's disease featuring localized asymmetric
frontotemporal atrophy.
Correct Answer: B. Creutzfeldt-Jakob disease,
characterized by rapid prion-mediated
neurodegeneration.
Rationale: Creutzfeldt-Jakob disease (CJD) is a rapidly
, progressive, fatal neurodegenerative prion disease
characterized by dementia and myoclonus. The presence
of periodic sharp wave complexes on an EEG at
approximately 1-second intervals is a classic diagnostic
feature that distinguishes CJD from more slowly
progressing cortical dementias.
2. A PMHNP is managing the pharmacological regimen of a
28-year-old female client diagnosed with schizophrenia
who has been stable on Clozapine 350 mg daily for the
past two years. During a routine monthly laboratory
follow-up, the absolute neutrophil count (ANC) returns at
1,250/mm³. What constitutes the most appropriate
clinical action under the current FDA Risk Evaluation and
Mitigation Strategy (REMS) guidelines?
A. Terminate clozapine instantly, admit the patient to an
acute psychiatric isolation ward, and initiate empirical
high-dose steroid therapy.
B. Continue the current clozapine dose, but increase the
ANC monitoring frequency to three times weekly until the
values return to a minimum baseline of 1,500/mm³.
C. Reduce the clozapine dosage by 50% immediately and
administer an intramuscular injection of a long-acting
typical antipsychotic agent to manage breakthrough
psychosis.
D. Continue standard monthly tracking under the
assumption that the ANC drop reflects a standard, benign
laboratory margin of error.
Correct Answer: B. Continue the current
clozapine dose, but increase the ANC monitoring
frequency to three times weekly until the values
return to a minimum baseline of 1,500/mm³.
Rationale: For an established clozapine patient, an
ANC between 1,000–1,499/mm³ is classified as Mild
Neutropenia under the FDA REMS protocol. The
, guideline instructs to continue clozapine therapy but
increase tracking to three times per week until the ANC
stabilizes or rises above 1,500/mm³.
3. A 19-year-old male college student is brought to the crisis
evaluation unit displaying acute state paranoia, extreme
visual hallucinations of crawling geometric matrices, a
resting heart rate of 124 beats per minute, severe
horizontal and vertical nystagmus, and a pronounced
reduction in pain sensitivity. The field toxicology
screening reports the presence of phencyclidine (PCP).
What is the direct neurochemical mechanism of action of
this substance, and what is the primary safety concern for
the PMHNP?
A. Selective serotonin reuptake inhibition; risk of an
immediate acute hypertensive stroke.
B. Non-competitive NMDA receptor antagonism; risk of
unpredictable, extreme physical violence and self-injury
due to profound analgesia.
C. Direct GABA-A receptor activation; risk of hyper-
reflexia and spontaneous localized skin desquamation.
D. Mu-opioid receptor agonism; risk of a catastrophic
rapid drop in intraocular eye pressures.
Correct Answer: B. Non-competitive NMDA
receptor antagonism; risk of unpredictable,
extreme physical violence and self-injury due to
profound analgesia.
Rationale: PCP acts primarily as a non-competitive
NMDA glutamate receptor antagonist. Clinically, it
causes a dissociative anesthetic state marked by
vertical/horizontal nystagmus, tachycardia, and a loss of
pain sensation, which often drives severe, unpredictable
combative behavior.
4. A 64-year-old male client with a history of chronic
industrial chemical exposure is referred to the clinic for a
, comprehensive diagnostic assessment. The PMHNP notes
the gradual development of a resting "pill-rolling" tremor,
a rigid "cogwheel" resistance during passive elbow
extension, a masked facial expression, and a shuffling gait.
Neuroanatomically, these motor signs reflect a severe loss
of dopaminergic neurons within which specific brain
region?
A. The locus coeruleus within the upper brainstem matrix.
B. The nucleus accumbens located within the ventral
striatum loop.
C. The substantia nigra pars compacta, projecting directly
to the basal ganglia via the nigrostriatal pathway.
D. The raphe nuclei, distributing specialized signaling
along the limbic network.
Correct Answer: C. The substantia nigra pars
compacta, projecting directly to the basal ganglia
via the nigrostriatal pathway.
Rationale: The classic triad of parkinsonian motor
signs (tremor, rigidity, bradykinesia) is caused by the
degeneration of dopaminergic projections from the
substantia nigra pars compacta to the striatum. This
nigrostriatal pathway is vital for coordinating smooth,
intentional muscle motor control.
5. A PMHNP is evaluating a 31-year-old female client who
reports a 3-week history of intense, persistent depressive
mood, anhedonia, a 12-pound weight loss, and terminal
insomnia. The client's record reveals a history of a full
manic episode four years ago following a major corporate
promotion. What is the correct diagnostic classification for
this client's current clinical presentation?
A. Major Depressive Disorder, recurrent episode with
seasonal melancholy features.
B. Bipolar I Disorder, current episode depressed, based on
the documented history of a past manic episode.
CERTIFICATION EXAM MASTERY
VAULT DETAILED CORRECT
ANSWERS WITH RATIONALES
AND CORRECT VERIFIED
ANSWERS FOR A GRADE A+
PERFORMANCE
1. A 42-year-old corporate executive presents with a 7-month
history of progressive cognitive deterioration, distinct
memory gaps, and involuntary, sudden jerking
movements of his upper extremities. The Psychiatric-
Mental Health Nurse Practitioner (PMHNP) orders an
electroencephalogram (EEG), which demonstrates a
classic diagnostic profile of periodic, sharp wave
complexes occurring at 1-second intervals. Given this
clinical presentation and neurophysiological profile, what
is the most likely diagnosis?
A. Early-onset Alzheimer's type dementia with pseudo-
bulbar symptoms.
B. Creutzfeldt-Jakob disease, characterized by rapid prion-
mediated neurodegeneration.
C. Wernicke-Korsakoff syndrome secondary to chronic
thiamine malabsorption.
D. Pick's disease featuring localized asymmetric
frontotemporal atrophy.
Correct Answer: B. Creutzfeldt-Jakob disease,
characterized by rapid prion-mediated
neurodegeneration.
Rationale: Creutzfeldt-Jakob disease (CJD) is a rapidly
, progressive, fatal neurodegenerative prion disease
characterized by dementia and myoclonus. The presence
of periodic sharp wave complexes on an EEG at
approximately 1-second intervals is a classic diagnostic
feature that distinguishes CJD from more slowly
progressing cortical dementias.
2. A PMHNP is managing the pharmacological regimen of a
28-year-old female client diagnosed with schizophrenia
who has been stable on Clozapine 350 mg daily for the
past two years. During a routine monthly laboratory
follow-up, the absolute neutrophil count (ANC) returns at
1,250/mm³. What constitutes the most appropriate
clinical action under the current FDA Risk Evaluation and
Mitigation Strategy (REMS) guidelines?
A. Terminate clozapine instantly, admit the patient to an
acute psychiatric isolation ward, and initiate empirical
high-dose steroid therapy.
B. Continue the current clozapine dose, but increase the
ANC monitoring frequency to three times weekly until the
values return to a minimum baseline of 1,500/mm³.
C. Reduce the clozapine dosage by 50% immediately and
administer an intramuscular injection of a long-acting
typical antipsychotic agent to manage breakthrough
psychosis.
D. Continue standard monthly tracking under the
assumption that the ANC drop reflects a standard, benign
laboratory margin of error.
Correct Answer: B. Continue the current
clozapine dose, but increase the ANC monitoring
frequency to three times weekly until the values
return to a minimum baseline of 1,500/mm³.
Rationale: For an established clozapine patient, an
ANC between 1,000–1,499/mm³ is classified as Mild
Neutropenia under the FDA REMS protocol. The
, guideline instructs to continue clozapine therapy but
increase tracking to three times per week until the ANC
stabilizes or rises above 1,500/mm³.
3. A 19-year-old male college student is brought to the crisis
evaluation unit displaying acute state paranoia, extreme
visual hallucinations of crawling geometric matrices, a
resting heart rate of 124 beats per minute, severe
horizontal and vertical nystagmus, and a pronounced
reduction in pain sensitivity. The field toxicology
screening reports the presence of phencyclidine (PCP).
What is the direct neurochemical mechanism of action of
this substance, and what is the primary safety concern for
the PMHNP?
A. Selective serotonin reuptake inhibition; risk of an
immediate acute hypertensive stroke.
B. Non-competitive NMDA receptor antagonism; risk of
unpredictable, extreme physical violence and self-injury
due to profound analgesia.
C. Direct GABA-A receptor activation; risk of hyper-
reflexia and spontaneous localized skin desquamation.
D. Mu-opioid receptor agonism; risk of a catastrophic
rapid drop in intraocular eye pressures.
Correct Answer: B. Non-competitive NMDA
receptor antagonism; risk of unpredictable,
extreme physical violence and self-injury due to
profound analgesia.
Rationale: PCP acts primarily as a non-competitive
NMDA glutamate receptor antagonist. Clinically, it
causes a dissociative anesthetic state marked by
vertical/horizontal nystagmus, tachycardia, and a loss of
pain sensation, which often drives severe, unpredictable
combative behavior.
4. A 64-year-old male client with a history of chronic
industrial chemical exposure is referred to the clinic for a
, comprehensive diagnostic assessment. The PMHNP notes
the gradual development of a resting "pill-rolling" tremor,
a rigid "cogwheel" resistance during passive elbow
extension, a masked facial expression, and a shuffling gait.
Neuroanatomically, these motor signs reflect a severe loss
of dopaminergic neurons within which specific brain
region?
A. The locus coeruleus within the upper brainstem matrix.
B. The nucleus accumbens located within the ventral
striatum loop.
C. The substantia nigra pars compacta, projecting directly
to the basal ganglia via the nigrostriatal pathway.
D. The raphe nuclei, distributing specialized signaling
along the limbic network.
Correct Answer: C. The substantia nigra pars
compacta, projecting directly to the basal ganglia
via the nigrostriatal pathway.
Rationale: The classic triad of parkinsonian motor
signs (tremor, rigidity, bradykinesia) is caused by the
degeneration of dopaminergic projections from the
substantia nigra pars compacta to the striatum. This
nigrostriatal pathway is vital for coordinating smooth,
intentional muscle motor control.
5. A PMHNP is evaluating a 31-year-old female client who
reports a 3-week history of intense, persistent depressive
mood, anhedonia, a 12-pound weight loss, and terminal
insomnia. The client's record reveals a history of a full
manic episode four years ago following a major corporate
promotion. What is the correct diagnostic classification for
this client's current clinical presentation?
A. Major Depressive Disorder, recurrent episode with
seasonal melancholy features.
B. Bipolar I Disorder, current episode depressed, based on
the documented history of a past manic episode.
